Azithromycin Add-On Fails to Cut Malaria Deaths, Hospital Stays - MedPage Today

-

Adding azithromycin to malaria chemoprevention did not reduce incidence of death or hospitalization among African children compared with placebo, a randomized trial found.

In an intent-to-treat analysis, there were 250 deaths or hospital admissions among the azithromycin group versus 238 in the placebo group (IRR 1.1, 95% CI 0.88-1.3), reported Daniel Chandramohan, PhD, of the London School of Hygiene and Tropical Medicine, and colleagues.

However, those in the azithromycin group had less frequent rates of gastrointestinal infections, upper respiratory tract infections, and non-malarial febrile illnesses, the authors wrote in the New England Journal of Medicine

These findings were also presented at the World Health Organization executive board meeting currently being held in Geneva.

Mass administration of azithromycin has helped with trachoma control, the authors said, as well as reductions in skin, GI, and upper respiratory infection. But they noted the "surprising" results of a trial in Ethiopia that found a 49% reduction in all-cause mortality among young children the year after mass administration of the drug.

Chandramohan's group enrolled children, ages 3 to 59 months, in Burkina Faso and Mali to receive sulfadoxine-pyrimethamine plus amodiaquine during peak malaria transmission season, and were assigned to receive 100 mg azithromycin or matching placebo. These combinations were administered in four 3-day cycles, at monthly intervals for three successive malaria transmission seasons, the authors said.

The study's primary endpoint was death or hospital admission for ≥24 hours that was not due to trauma or elective surgery during the intervention period.

Overall, 19,578 children were randomized -- 9,735 to the azithromycin group and 9,843 to the control group. Children would exit the trial when they reached age 5 years, the authors said, and new children were enrolled. At the last follow-up visit, there were 10,885 children in the azithromycin group and 10,852 in the control group.

While there was no reduction in deaths or hospitalizations in the azithromycin group versus placebo, the authors found evidence of an interaction between trial group and trial site. They noted that the incidence of the primary endpoint was higher in the azithromycin group in Burkina Faso (IRR 1.3, 95% CI 1.0-1.7) but not in Mali (IRR 0.84, 95% CI 0.64-1.1). But they added that "no plausible mechanism to explain this difference was found, and given the borderline increased incidence in Burkina Faso, it may be a chance finding."

When examining clinic visits for certain events, the azithromycin group had a lower incidence than the placebo group of the following:

  • GI infections: IRR 0.85 (95% CI 0.79-0.91)
  • Upper respiratory tract infections: IRR 0.85 (95% CI 0.81-0.90)
  • Non-malarial fevers: IRR 0.79 (95% CI 0.73-0.87)

Moreover, an exploratory analysis found that incidence of skin diseases, especially those with a bacterial cause, was lower in the azithromycin group, the authors said, which was "consistent with findings of previous studies in which azithromycin was used in trachoma control programs." They also found the prevalence of malaria parasitemia was similar between the two groups.

There were no severe adverse events related to the trial drugs, and diarrhea was the most frequent adverse event. Incidence of adverse events were similar between groups, the authors noted.

Study limitations included the fact that randomization was performed according to household versus village, which reduced the potential for bias, but precluded the potential for a herd effect. The authors also cited "limited safety data" because both seasonal malaria chemoprevention and mass administration of azithromycin "have now been given to millions of children with no major safety concerns."

This study was supported by grants from the Joint Global Health Trials scheme, including the U.K. Medical Research Council (UKMRC), the Department for International Development, the National Institute for Health Research, and the Wellcome Trust.

Chandramohan disclosed no relevant relationships with industry. C-authors disclosed grants from UKMRC.

2019-01-30T17:00:00-0500


http://bit.ly/2G1htFC

Comments

Post a Comment

Popular posts from this blog

Manual on meat inspection for developing countries

-
Image
sinusitis treatment :: Article Creator My 'sinus Infection' Turned Out To Be A One In A Million Nasal Cancer At Just 28 - And Doctors Had To Cut My Eye Out To Save Me By Emily Joshu Health Reporter For Dailymail.Com Published: 06:33 EDT, 20 April 2024Updated: 06:35 EDT, 20 April 2024 A 28 year-old California woman has described the shock of being diagnosed with a deadly sinus cancer that affects fewer than one in a million people - and led to the removal of her right eye. The 'golf ball-sized tumor', which had spread throughout her face, was first mistaken for a sinus infection by the woman's doctors.  Annika, who posts about her condition on TikTok, woke up one morning in 2023 and noticed that the inner corner of her right eye was sore.  While she at first thought nothing of it, by the time the evening rolled around, 'my face started to really, really hurt on the right side,' she said in a video.  The next day, her
Read more

Rash behind ear: Causes, other symptoms, and treatment - Medical News Today

-
Image
A rash behind the ear may occur due to a variety of different medical conditions. Certain viral infections and autoimmune diseases may cause a rash behind the ear in both children and adults. While some causes, such as contact dermatitis, are not concerning, other causes, including rubella, may be more serious. In this article, we look at some of the causes of a rash behind the ear, as well as the other symptoms that they may produce and how to treat them. Contact dermatitis is an allergic reaction to a particular substance. If an allergy-inducing substance comes into contact with the skin behind the ear, a rash can form. Allergens that may cause contact dermatitis behind the ears include: shampoos soaps other hair care products For example, hair dye products contain an ingredient called paraphenylenediamine (PPD), which is a common contact allergen. Symptoms Contact dermatitis causes itchiness, dryness, and flaking of the skin that came into contact with the allergen. Diagnosis A doc
Read more

Having This One Particular Blood Type Can Help Protect You From Severe Malaria - ScienceAlert

-
Image
Nearly  half the world's population is at risk of malaria, one of the most deadly diseases known to humankind. Each year it claims  over 400,000 lives, most of whom are children younger than age five. While it's possible to vaccinate against malaria, virtually all of these cases are in the African region, where protection is often nothing more than a roll of the dice. Now, a recent  analysis  of 23 papers suggests those with blood type O have the genetic odds stacked in their favour. In sub-Saharan Africa, where severe malaria - caused by the  Plasmodium falciparum  parasite  - is endemic, there are far more individuals with blood type O than anywhere in Europe or the US. In Nigeria alone, where 97 percent of the country is at risk of malaria, more than half the population belongs to this blood group. In Ethiopia and many others, the numbers are similar. Rather than a coincidence, co-author and epidemiologist Abraham Degarege Mengist from Robert Stempel College of Publi
Read more